Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)

MLA

de Boer, Rudolf A., et al. “Targeted Therapies in Genetic Dilated and Hypertrophic Cardiomyopathies: From Molecular Mechanisms to Therapeutic Targets. A Position Paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC).” European Journal of Heart Failure, vol. 24, no. 3, Mar. 2022, pp. 406–20. EBSCOhost, https://doi.org/10.1002/ejhf.2414.

APA

de Boer, R. A., Heymans, S., Backs, J., Carrier, L., Coats, A. J. S., Dimmeler, S., Eschenhagen, T., Filippatos, G., Gepstein, L., Hulot, J., Knöll, R., Kupatt, C., Linke, W. A., Seidman, C. E., Tocchetti, C. G., van der Velden, J., Walsh, R., Seferovic, P. M., & Thum, T. (2022). Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). European Journal of Heart Failure, 24(3), 406–420. https://doi.org/10.1002/ejhf.2414

Chicago

de Boer, Rudolf A., Stephane Heymans, Johannes Backs, Lucie Carrier, Andrew J.S. Coats, Stefanie Dimmeler, Thomas Eschenhagen, et al. 2022. “Targeted Therapies in Genetic Dilated and Hypertrophic Cardiomyopathies: From Molecular Mechanisms to Therapeutic Targets. A Position Paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC).” European Journal of Heart Failure 24 (3): 406–20. doi:10.1002/ejhf.2414.